
    
      To evaluate the safety and preliminary efficacy of recombinant anti-PD-L1（Programmed cell
      death ligand 1）monoclonal antibody injection (ZKAB001) combined with carboplatin and
      etoposide in the treatment of extensive-stage small cell lung cancer. The study will last
      until the number of patients who permanently stop taking drugs due to toxicity in the first
      two cycles is less than 1/3 of the total number of patients.
    
  